5. Summary of cost‐effectiveness studies.
| Lubell 2009 | Lubell 2011 | |
| Location(s) | Asia | Sub‐Saharan Africa |
| Population | Mostly adults (86%) | Children |
| Type of analysis | Cost‐effectiveness | Cost‐effectiveness |
| Perspective taken | Provider | Provider |
| Main cost categories | Drug cost (but not administration costs) Inpatient care cost |
Drugs Fluids Laboratories Hotel |
| Currency | USD | USD |
| Price year | 2008 | 2009 |
| Sensitivity analysis? | Yes | Yes |
| Time horizon | Immediate | Immediate |
| Total cost per treatment episode artesunate vs. quinine | $43.0 vs. $32.4 | $66.5 vs. $63.5 |
| Number needed to treat | 13 | 41 |
| Incremental cost per death averted | $135.6 | $123 |
| Incremental cost per DALY averted | Not calculated | $3.8 |